Clinical trial data have not shown increased risk of these malignancies
Structural insights into conformational stability of both wild-type and mutant EZH2 receptor
the data from these two large, well-powered clinical trials will provide robust evidence on the cardiovascular and metabolic benefits of tirzepatide, potentially expanding the treatment options for adults with T2DM, obesity, and related cardiovascular complications [7] (Clinical Traials.gov)
The SUSTAIN-6 Trial (Once-Weekly Semaglutide) The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) consisted of 3297 people living with T2DM, 83% with established cardiovascular disease, receiving once-weekly semaglutide (0.5 and 1.0 mg) or placebo
Patients with stronger GIPR variants may benefit more from tirzepatide
Here are some practical tips: Start gradually: Begin with a gentler fasting schedule, like 12:12, before progressing to longer fasting windows